Called one of the 50 most influential people in Regenerative Medicine, Eduardo Bravo is currently the CEO of Nordic Nanovector, a company focused on a unique combo therapy combining a monoclonal antibody with a radiation therapy. He successfully steered the stem cell company TiGenix through a rejected FDA application and re-emerge with a new product portfolio to be successfully acquired in 2018 by Takeda in an all cash deal valued over $600 mil. Eduardo is also the former president of the trade body European Biopharmaceutical Enterprises (EBE), and led several initiatives to help Europe’s competitiveness in the biotech sector. In this podcast we discuss the looming international debates on drug pricing as well as the challenges to commercialisation in Europe.

See omnystudio.com/listener for privacy information.

For thirty years, Richard Barker has been one of the U.K.’s healthcare thought leaders. He is the Founder of New Medicine Partners and the Founding Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI), where he championed the concept of adaptive licensing. With the current U.S. focus on international reference pricing for Medicare Part D & B, Richard’s work in Adaptive Reimbursement is gaining traction as a potential solution to pricing debates that are currently reaching a global crescendo.

Dr Barker was the Director General of the Association of the British Pharmaceutical Industry (ABPI) for six years between 2004 and 2011, and intimately understands both NHS budget constraints, as well as the need for a vibrant investment ecosystem to make healthcare innovation a reality. Richard is currently Chairman of the Health Innovation Network of South London, and a member of the Celgene board of Directors. He is the former EU head of McKinsey’s Healthcare practice and was also the General Manager of IBM's healthcare business.

See omnystudio.com/listener for privacy information.

Recorded in July of 2019, this podcast features Sue Peschin, the President and CEO of the Alliance for Aging Research in Washington DC, which is an organisation currently at the centre of the current Medicare Part B and Part D debates. Sue has more than 20 years of experience in health policy roles and has led Alliance since 2012. She has driven efforts in adult immunization, NIH Alzheimer’s funding, cardiovascular disease, and co-organized the first-ever NIH geriatric medicine summit. She participates in many major industry and policy symposiums around the United States each year and has published many opinion pieces in leading news outlets nationwide.

See omnystudio.com/listener for privacy information.

Susan Cantrell is the CEO of the Academy of Managed Care Pharmacy (AMCP), the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.

AMCP advocates at the national and state level for developing and applying evidence-based medication use strategies that improve access to medication, enhance patient and population health outcomes, and safeguard the wise use of health care dollars.
Before AMCP, Susan was Senior Vice President and Managing Director, Americas for the Drug Information Association (DIA). She is also a registered pharmacist and former hospital and home care pharmacy administrator.

See omnystudio.com/listener for privacy information.

John Doyle leads the Patient Health & Impact Global Healthcare Innovation Center at Pfizer. His team designs new models for value-based contracting and innovative financing and forges new partnerships across the healthcare sector to facilitate value-based healthcare. Prior to joining Pfizer, John led the Global Enterprise Solutions team at IQVIA, providing technology-enabled real world evidence platforms and research networks to healthcare systems worldwide. John also led the Global Value & Outcomes Center of Excellence at Quintiles, overseeing pricing and market access, policy analysis, and health economics and outcomes research.

Recorded live at the 2019 BIO international conference in Philadelphia, this podcast includes in-depth discussions on what value-based pricing is and the challenges to its implementation. John also discusses the Administration’s International Reference Pricing Initiative and offers alternatives that focus on bringing better value to US patients without limiting access.

See omnystudio.com/listener for privacy information.

With the future of the EU HTA Regulation in question, Niklas Hedberg, Chair of the EUnetHTA Executive Board, discusses what’s needed to get the HTA Proposal back on track. Recorded at the HTAi conference in Köln, Niklas also expresses his opinions on the state of the OMP legislation from the standpoint of both EUnetHTA and his home HTA in Sweden, and does so incorporating the discussions around the orphan legislation at the conference.

Niklas Hedberg is the Chief Pharmacist of the Swedish Pharmaceutical Benefits Agency (TLV) and a frequent presenter at leading conferences such as DIA and ISPOR. He is seen as one of Europe’s young visionaries, working to develop new approaches to evaluating medicines in the member states while also improving access for patients.

See omnystudio.com/listener for privacy information.

In this podcast we discuss the evolution of science that is driving the increasing focus on rare indications with Anne Pariser, the Director of the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS). Anne is a noted international expert or rare diseases, and has been involved in numerous collaborations within the FDA, as well as with drug developers, governmental agencies, patient groups and other stakeholders in the development of treatments for rare indications.

Dr Pariser comes to NCATS from the FDA, where she had worked since 2000 on the development of drug and biological products for orphan and rare conditions. Dr Pariser also served as an associate director in the FDA’s Office of Translational Sciences, which is part of the Center for Drug Evaluation and Research (CDER).

See omnystudio.com/listener for privacy information.

Peter Young is a Venture Partner at Pappas Capital, and brings to his investment approach thirty-five years of experience in the biopharma sector. The former Vice President and Therapy Head at Glaxo Wellcome in the mid-1990s, Peter led the global introduction of combination HIV therapies that revolutionized HIV treatment, quintupled Glaxo’s HIV sales, and maintained leadership on global treatment access. Peter has since served as CEO of two private start-ups, a vaccine company that raised over $80 million in NIH, HIV, and biodefense grants, and a specialty pharmaceutical company he led to a successful exit.

In a podcast recorded at the BIO International conference, Peter discusses the ramifications of the Trump Administration’s proposals for international reference pricing in Medicare Part B, as well as how to balance the higher prices being driven by smaller, targeted indications and the need to support the natural movement of science in rare therapies. We also discuss the ‘hot-button’ issues around the orphan drug legislation and how we can constructively move forward without throwing the orphan baby out with the bathwater.

This podcast is made possible with the support of EUCOPE.

See omnystudio.com/listener for privacy information.

EURORDIS, a portmanteau of European Rare Disease, is a non-governmental alliance of organisations representing 860 rare disease patient organisations in 70 countries, and the 30 million people affected by rare diseases throughout Europe. CEO Yann Le Cam in 1997, one of the founders of EURORDIS, who's eldest of three daughters is living with cystic fibrosis.

With the upcoming European Commission Conference on Rare Diseases occurring on June 17th coupled with the ongoing inquiry around the OMP regulation, this timely podcast with EURORDIS’ Director of Public Affairs, Simone Boselli, puts the discussions squarely in the context of patient access to needed medicines for rare indications by developing a pan-European value-based evaluation network.

This Better Science, Better Health Podcast is made possible with the support of EUCOPE.

See omnystudio.com/listener for privacy information.

Erik Tambuyzer is one of the world’s thought leaders in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics. As an entrepreneur in 1985, he had co-founded and managed the biotech company Innogenetics, ultimately acquired by Fujirebio. He is the Executive Chairperson and co-founder of the BioPontis Alliance for Rare Diseases, an international philanthropic foundation turning science into medicines.

This Better Science, Better Health Podcast is made possible with the support of EUCOPE.

See omnystudio.com/listener for privacy information.